A Validated Risk Score for Venous Thromboembolism Is Predictive of Cancer Progression and Mortality.

Area of Science:

• Oncology
• Hematology
• Clinical Epidemiology

Background:

• Retrospective studies suggest a link between cancer-associated venous thromboembolism (VTE) and patient survival.
• A validated VTE Clinical Risk Score was previously developed to predict VTE occurrence.
• This study aimed to evaluate the score's utility in predicting early mortality and cancer progression.

Purpose of the Study:

• To assess the predictive accuracy of a VTE Clinical Risk Score for early mortality and cancer progression in cancer patients receiving chemotherapy.
• To determine if the VTE Clinical Risk Score is an independent predictor of adverse outcomes beyond VTE itself.

Main Methods:

• A prospective, nationwide cohort study of 4,405 adult patients with solid tumors or lymphoma initiating chemotherapy.
• Survival and cancer progression data were collected and analyzed using Kaplan-Meier and Cox regression methods.
• The VTE Clinical Risk Score was used to categorize patients into low, intermediate, and high-risk groups.

Main Results:

• High-risk patients (12.3%) had a 12.7% 120-day mortality rate (aHR 3.00) and 27.2% cancer progression rate (aHR 2.2).
• Intermediate-risk patients (60.5%) had a 5.9% mortality rate (aHR 2.3) and 16.4% progression rate (aHR 1.9).
• Low-risk patients (27.2%) experienced significantly lower rates of mortality (1.4%) and progression (8.5%).

Conclusions:

• The VTE Clinical Risk Score effectively predicts early mortality and cancer progression in patients receiving outpatient chemotherapy.
• The score's predictive power is independent of other major prognostic factors, including VTE itself.
• Further research is needed to investigate the impact of VTE prophylaxis on survival outcomes.